Hematology

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AbbVie) M16-191A Randomized, Open-Label, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib Alone In Subjects With MyelofibrosisLeber, Dr BrianOpen to recruitmentNCT04472598
(AbbVie) M19-708 / VIALE-MRandomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)Leber, Dr BrianOpen to recruitmentNCT04102020
(AbbVie) M20-178 / TRANSFORM-2A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in
Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory
Myelofibrosis (TRANSFORM-2)
Leber, Dr BrianOpen to recruitmentNCT04468984
(Celgene) ACE-536-MDS-002 / COMMANDSA Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell TransfusionsLeber, Dr BrianOpen to recruitmentNCT03682536
(Constellation) CPI-0610-02 / MANIFEST studyA Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)Leber, Dr BrianOpen to recruitmentNCT02158858
(Horizon Health Network) The M4 Study The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Cohort Study (The M4 Study) Mian, Dr HiraOpen to recruitmentNCT03421132
(McMaster) CTTC 1901 / OZM-099A Randomized Pilot Trial comparing Anti-Thymocyte Globulin (ATG) with ATG plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)Walker, Dr IrwinOpen to recruitmentNCT04202835
(Novartis) CCTL019B2302A Phase IIIb Study of the Safety and Efficacy of Tisagenlecleucel Out of Specification for Commercial Release in Patients Who Are Consistent With the Label IndicationKouroukis, Dr TomOpen to recruitmentNCT04094311
CMRG 007 / MCRN 007 / ALGONQUINA Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the Recommended Phase 2 Dose, Safety and Efficacy of the Antibody Drug Conjugate GSK2857916 in Combination with Pomalidomide and Low-Dose Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM)Mian, Dr HiraOpen to recruitmentNCT03715478
(CCTG) LY.17A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaFraser, Dr GraemeSuspended/On holdNCT02436707
(Celgene) CC-97540-NHL-001A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CC-97540, CD19-TARGETED NEX-T CHIMERIC
ANTIGEN RECEPTOR (CAR) T CELLS, IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL NONHODGKIN LYMPHOMA
Foley, Dr RonanSuspended/On holdNCT04231747
CMRG 008A Phase 2 Multi-Center, Open Label Study of Isatuximab added to standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple MyelomaMian, Dr HiraSuspended/On holdNCT04786028
Download PDF